OBJECTIVE: Autosomal dominant parkinsonism, hypoventilation, depression and severe weight loss (Perry syndrome) is an early-onset rapidly progressive disease. At autopsy, previous studies have found severe neuronal loss in the substantia nigra without Lewy bodies. Transactive response DNA-binding protein of 43 kDa (TDP-43) has recently been identified as a major ubiquitinated constituent of neuronal and glial inclusions in frontotemporal lobar degeneration with ubiquitin-positive inclusions and in amyotrophic lateral sclerosis. This study reports clinical, genetic and neuropathologic investigations of Perry syndrome. METHODS: Clinical data and autopsy brain tissue samples were collected from eight patients from four genealogically unrelated kindreds with Perry syndrome. Brain tissue was studied with immunohistochemistry and biochemistry for TDP-43. Patients were screened for mutations in the progranulin (GRN) and TDP-43 (TARDBP) genes. RESULTS: The mean age at onset was 47 years (range 40-56), and the mean age at death was 52 years (range 44-64). In all patients, we identified TDP-43-positive neuronal inclusions, dystrophic neurites and axonal spheroids in a predominantly pallidonigral distribution, and we demonstrated changes in solubility and electrophoretic mobility of TDP-43 in brain tissue. The inclusions were highly pleomorphic and predominated in the extrapyramidal system, sparing the cortex, hippocampus and motor neurons. There were no mutations in GRN or TARDBP. INTERPRETATION: Perry syndrome displays unique TDP-43 pathology that is selective for the extrapyramidal system and spares the neocortex and motor neurons.
OBJECTIVE:Autosomal dominant parkinsonism, hypoventilation, depression and severe weight loss (Perry syndrome) is an early-onset rapidly progressive disease. At autopsy, previous studies have found severe neuronal loss in the substantia nigra without Lewy bodies. Transactive response DNA-binding protein of 43 kDa (TDP-43) has recently been identified as a major ubiquitinated constituent of neuronal and glial inclusions in frontotemporal lobar degeneration with ubiquitin-positive inclusions and in amyotrophic lateral sclerosis. This study reports clinical, genetic and neuropathologic investigations of Perry syndrome. METHODS: Clinical data and autopsy brain tissue samples were collected from eight patients from four genealogically unrelated kindreds with Perry syndrome. Brain tissue was studied with immunohistochemistry and biochemistry for TDP-43. Patients were screened for mutations in the progranulin (GRN) and TDP-43 (TARDBP) genes. RESULTS: The mean age at onset was 47 years (range 40-56), and the mean age at death was 52 years (range 44-64). In all patients, we identified TDP-43-positive neuronal inclusions, dystrophic neurites and axonal spheroids in a predominantly pallidonigral distribution, and we demonstrated changes in solubility and electrophoretic mobility of TDP-43 in brain tissue. The inclusions were highly pleomorphic and predominated in the extrapyramidal system, sparing the cortex, hippocampus and motor neurons. There were no mutations in GRN or TARDBP. INTERPRETATION:Perry syndrome displays unique TDP-43 pathology that is selective for the extrapyramidal system and spares the neocortex and motor neurons.
Authors: Keith A Josephs; Zeshan Ahmed; Omi Katsuse; Joseph F Parisi; Bradley F Boeve; David S Knopman; Ronald C Petersen; Peter Davies; Ranjan Duara; Neill R Graff-Radford; Ryan J Uitti; Rosa Rademakers; Jennifer Adamson; Matthew Baker; Michael L Hutton; Dennis W Dickson Journal: J Neuropathol Exp Neurol Date: 2007-02 Impact factor: 3.685
Authors: Manuela Neumann; Ian R Mackenzie; Nigel J Cairns; Philip J Boyer; William R Markesbery; Charles D Smith; J Paul Taylor; Hans A Kretzschmar; Virginia E Kimonis; Mark S Forman Journal: J Neuropathol Exp Neurol Date: 2007-02 Impact factor: 3.685
Authors: Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee Journal: Science Date: 2006-10-06 Impact factor: 47.728
Authors: Ian R A Mackenzie; Atik Baborie; Stuart Pickering-Brown; Daniel Du Plessis; Evelyn Jaros; Robert H Perry; David Neary; Julie S Snowden; David M A Mann Journal: Acta Neuropathol Date: 2006-09-26 Impact factor: 17.088
Authors: David B Wang; Robert D Dayton; Phillip P Henning; Cooper D Cain; Li Ru Zhao; Lisa M Schrott; Elysse A Orchard; David S Knight; Ronald L Klein Journal: Mol Ther Date: 2010-09-28 Impact factor: 11.454
Authors: Andre C Felicio; Katherine Dinelle; Pankaj A Agarwal; Jessamyn McKenzie; Nicole Heffernan; Jeremy D Road; Silke Appel-Cresswell; Zbigniew K Wszolek; Matthew J Farrer; Michael Schulzer; Vesna Sossi; A Jon Stoessl Journal: Mov Disord Date: 2014-05-05 Impact factor: 10.338
Authors: Takuya Konno; Owen A Ross; Hélio A G Teive; Jarosław Sławek; Dennis W Dickson; Zbigniew K Wszolek Journal: Parkinsonism Relat Disord Date: 2017-06-12 Impact factor: 4.891
Authors: Shunsuke Koga; Monica Sanchez-Contreras; Keith A Josephs; Ryan J Uitti; Neill Graff-Radford; Jay A van Gerpen; William P Cheshire; Zbigniew K Wszolek; Rosa Rademakers; Dennis W Dickson Journal: Mov Disord Date: 2016-12-23 Impact factor: 10.338
Authors: Michael A Gitcho; Eileen H Bigio; Manjari Mishra; Nancy Johnson; Sandra Weintraub; Marsel Mesulam; Rosa Rademakers; Sumi Chakraverty; Carlos Cruchaga; John C Morris; Alison M Goate; Nigel J Cairns Journal: Acta Neuropathol Date: 2009-07-18 Impact factor: 17.088